Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology

Reuters01-22

Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology

Venus MedTech Hangzhou Inc. has provided an update regarding ongoing patent litigation in the United States. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards Lifesciences in the United States District Court for the District of Delaware. The case concerns the alleged infringement of the US patent 10,702,385, which covers an implant for heart valves and is owned by Cardiovalve Ltd. The lawsuit follows a June 2025 decision by the US Court of Appeals for the Federal Circuit affirming the patentability of certain claims of this patent, after they were challenged by Edwards Lifesciences in an inter partes review. Venus MedTech has advised its shareholders and potential investors to exercise caution in dealings related to its shares while the litigation is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11997951), on January 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605599824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605599824","market":"nz","top_or_hot":-1,"title":"Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Venus MedTech Hangzhou Inc. has provided an update regarding ongoing patent litigation in the United States. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards Lifesciences in the United States District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a>. The case concerns the alleged infringement of the US patent 10,702,385, which covers an implant for heart valves and is owned by Cardiovalve Ltd. The lawsuit follows a June 2025 decision by the US Court of Appeals for the Federal Circuit affirming the patentability of certain claims of this patent, after they were challenged by Edwards Lifesciences in an inter partes review. Venus MedTech has advised its shareholders and potential investors to exercise caution in dealings related to its shares while the litigation is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11997951), on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVenus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-22 12:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Venus MedTech Hangzhou Inc. has provided an update regarding ongoing patent litigation in the United States. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards Lifesciences in the United States District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a>. The case concerns the alleged infringement of the US patent 10,702,385, which covers an implant for heart valves and is owned by Cardiovalve Ltd. The lawsuit follows a June 2025 decision by the US Court of Appeals for the Federal Circuit affirming the patentability of certain claims of this patent, after they were challenged by Edwards Lifesciences in an inter partes review. Venus MedTech has advised its shareholders and potential investors to exercise caution in dealings related to its shares while the litigation is ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11997951), on January 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL7wcT4n:1","article_id":"2605599824","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605599824","pubTimestamp":1769054485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Venus MedTech Hangzhou Inc. has provided an update regarding ongoing patent litigation in the United States. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards Lifesciences in the United States District Court for the District of Delaware. The case concerns the alleged infringement of the US patent 10,702,385, which covers an implant for heart valves and is owned by Cardiovalve Ltd. The lawsuit follows a June 2025 decision by the US Court of Appeals for the Federal Circuit affirming the patentability of certain claims of this patent, after they were challenged by Edwards Lifesciences in an inter partes review. Venus MedTech has advised its shareholders and potential investors to exercise caution in dealings related to its shares while the litigation is ongoing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","BK1574":"生物医药B类股","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK1583":"高瓴概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4082":"医疗保健设备","BK4504":"桥水持仓","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4588":"碎股","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","EW":"爱德华兹","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","02500":"启明医疗-B"},"translate_title":"Venus MedTech面临心脏瓣膜技术专利侵权诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":0.9,"EW":0.9},"content_text":"Venus MedTech Faces Patent Infringement Lawsuit Over Heart Valve Technology\n    \n\n        Venus MedTech Hangzhou Inc. has provided an update regarding ongoing patent litigation in the United States. On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards Lifesciences in the United States District Court for the District of Delaware. The case concerns the alleged infringement of the US patent 10,702,385, which covers an implant for heart valves and is owned by Cardiovalve Ltd. The lawsuit follows a June 2025 decision by the US Court of Appeals for the Federal Circuit affirming the patentability of certain claims of this patent, after they were challenged by Edwards Lifesciences in an inter partes review. Venus MedTech has advised its shareholders and potential investors to exercise caution in dealings related to its shares while the litigation is ongoing.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260122-11997951), on January 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605599824","isCrawlerRequest":true}